Breaking The $100 Genome Barrier: How Ultima Genomics Is Revolutionizing DNA Sequencing With Gilad Almogy

FYI - For Your Innovation

Content provided by ARK Invest. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ARK Invest or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

29d ago 57:45

MP3•Episode home

DNA sequencing is on the cusp of a major transformation, and Gilad Almogy, CEO of Ultima Genomics, is leading the charge. In this episode of FYI, ARK’s Chief Futurist, Brett Winton, and Multiomics analyst Nemo Despot explore how Ultima is making whole-genome sequencing radically cheaper—driving costs down from $1,000 to just $80 per genome, with ambitions for even further reductions. Gilad shares how his background in semiconductors shaped Ultima’s innovative approach, which relies on cost-efficient silicon wafers and high-throughput sequencing. The conversation also dives into the massive potential applications for low-cost sequencing, from cancer diagnostics and population genomics to AI-driven drug discovery.

Key Points From This Episode:

How Ultima Genomics’ unique approach is slashing sequencing costs
The growing role of AI in understanding biology
Why sequencing demand is highly elastic—cheaper data unlocks new applications
The future of personalized medicine and real-time cancer detection
How population-scale genomics will transform healthcare

366 episodes

#Trading #Business #Tech News #ARK Investment Management LLC #ARK Invest #Future Trends #Tech #Podcasting Education